# Anti-BCMA CAR-T Cell Therapy for the R/R Multiple Myeloma

> **NCT04637269** · EARLY_PHASE1 · UNKNOWN · sponsor: **Xinqiao Hospital of Chongqing** · enrollment: 16 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **BIOLOGICAL:** anti-BCMA CAR-T

## Key facts

- **NCT ID:** NCT04637269
- **Lead sponsor:** Xinqiao Hospital of Chongqing
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-11-17
- **Primary completion:** 2021-11-01
- **Final completion:** 2023-11-01
- **Target enrollment:** 16 (ESTIMATED)
- **Last updated:** 2020-11-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04637269

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04637269, "Anti-BCMA CAR-T Cell Therapy for the R/R Multiple Myeloma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04637269. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*